Dostarlimab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dostarlimab and local guidelines before prescribing.
Immune checkpoint inhibitor
Mechanism
PD-1 inhibitor.
Uses
Endometrial and colorectal cancers with mismatch-repair deficiency.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Immune-related adverse events, fatigue, rash.
Interactions
Steroids reduce effect.
Contraindications and cautions
Autoimmune disease caution
Monitoring
TFT, LFT
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Immune toxicity pathway.
More from the textbook: uses, cautions and other points
- Carboplatin and paclitaxel with immunotherapy (dostarlimab or pembrolizumab - especially MMR-deficient).
Oncology: Breast and Gynae Cancers - Dostarlimab | Advanced endometrial cancer (especially MMR-deficient).
Oncology: Breast and Gynae Cancers - Anti-PD-1 - pembrolizumab , nivolumab , cemiplimab, dostarlimab.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology